Earnings results for AzurRx BioPharma (NASDAQ:AZRX)
AzurRx BioPharma, Inc. is estimated to report earnings on 09/22/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.25.
Analyst Opinion on AzurRx BioPharma (NASDAQ:AZRX)
3 Wall Street analysts have issued ratings and price targets for AzurRx BioPharma in the last 12 months. Their average twelve-month price target is $2.50, predicting that the stock has a possible upside of 228.82%. The high price target for AZRX is $3.00 and the low price target for AZRX is $2.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
AzurRx BioPharma has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $2.50, AzurRx BioPharma has a forecasted upside of 228.8% from its current price of $0.76. AzurRx BioPharma has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: AzurRx BioPharma (NASDAQ:AZRX)
AzurRx BioPharma does not currently pay a dividend. AzurRx BioPharma does not have a long track record of dividend growth.
Insiders buying/selling: AzurRx BioPharma (NASDAQ:AZRX)
In the past three months, AzurRx BioPharma insiders have not sold or bought any company stock. Only 7.30% of the stock of AzurRx BioPharma is held by insiders. Only 4.93% of the stock of AzurRx BioPharma is held by institutions.
Earnings and Valuation of AzurRx BioPharma (NASDAQ:AZRX
Earnings for AzurRx BioPharma are expected to grow in the coming year, from ($0.56) to ($0.35) per share. AzurRx BioPharma has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here